Adaptate Biotherapeutics Raises $18 million in Series A2 Funding
Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline
Latest financing takes total funds raised to $34 million
London, UK, 19th April 2021: Adaptate Biotherapeutics (Adaptate), a company focussed on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited (Takeda) have together made a further equity investment of $18 million (circa. £13 million). This funding brings the total raised since Adaptate’s inception in late 2019 to $34 million (circa. £25 million).
The investment results from the rapid progress made by the Company over the past 18 months. The funds will be used to accelerate the progression of Adaptate’s lead therapeutic antibody programme towards the clinic and to expand its internal product pipeline. The Company’s growing portfolio includes both monoclonal and bispecific antibodies which target gamma delta T cells, a unique class of lymphocytes that bridge innate and adaptive immunity. The Company’s most advanced programmes are focussed on treatments for cancer patients with solid tumours. Adaptate’s antibodies selectively target gamma delta T cells, thereby offering the opportunity for superior efficacy and safety compared to conventional immunomodulatory therapies such as pan T cell activators.
The financing will also support the Company’s expansion, including further recruitment and increased laboratory and office space. This expansion exemplifies Adaptate’s rapid growth plans and the additional capacity will play a key role in further boosting research and development activities.
Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “The funding is a great vote of confidence from our existing investors and testimony to the hard work and rapid progress we have made in the novel field of gamma delta T cell targeting antibodies. We are excited to continue this growth path and to progress our unique therapeutic antibodies towards clinical trials where we look forward to them making an impact on the treatments available to cancer patients.”
Tim Haines, Chairman & Managing Partner, Abingworth, commented: “We have been impressed with the potential of Adaptate’s therapeutic antibody technology and the significant progress to date.. We are delighted to invest further, to enable the team to accelerate its very promising portfolio towards the clinic.”
Loic Vincent, Head, Oncology Drug Discovery Unit, Takeda, added: “Takeda’s ongoing investment in Adaptate aligns closely with our pursuit of potentially life-changing treatments for cancer patients through novel immuno-oncology approaches. We look forward to continuing to work together on the potential of gamma delta T cell targeted therapies to achieve this goal.”